Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Ampligen
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==References== <references> <ref name="Ablashi, 1994">{{Citation | last1 = Ablashi | first1 = DV | author-link1 = Dharam Ablashi | last2 =Berneman | first2 = ZN | author-link2 = | last3 =Williams | first3 = M | author-link3 = | last4 = Strayer | first4 = D | author-link4 = David Strayer | last5 = Kramarsky | first5 = B | author-link5 = | last6 = Suhadolnik | first6 = RJ | author-link6 =Robert Suhadolnik | last7 =Reichenbach | first7 = N | author-link7 = | last8 = Hiltzges | first8 = P | author-link8 = | last9 = Komaroff | first9 = AL | author-link9 = Anthony Komaroff | title = Ampligen inhibits human herpesvirus-6 in vitro | journal =In Vivo | volume = 8 | issue = 4 | page = 587-91 | date = 1994 | pmid = 7893986 | doi = | url=| pages=|chapter=|edition=|isbn=}}</ref> <ref name="Crystal, 2016">{{citation | author= Crystal Research Associates | title = Hemispherx Biopharma, Inc. | type = Executive Informational Overview | date = 27 Nov 2016 | url = http://cdn2.hubspot.net/hubfs/150154/docs/Hemispherx-Executive-Informational-Overview-11-27-16.pdf }}</ref> <ref name="Strayer, 2015">{{Citation | last1 = Strayer | first1 = David R | author-link1 = David Strayer | last2 = Stouch | first2 = Bruce C | author-link2 = | last3 = Stevens | first3 = Staci R. | author-link3 = Staci Stevens | last4 = Bateman | first4 = Lucinda| author-link4 = Lucinda Bateman | last5 = Lapp | first5 = Charles W | author-link5 = Charles Lapp | last6 = Peterson | first6 = Daniel L | author-link6 = Daniel Peterson | last7 = Carter | first7 = William A | author-link8 = William Carter | last8 = Mitchell | first8 = William M | author-link8 = William Mitchell | title = Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod | journal =Journal of Drug Research and Development | volume = 1 | issue = 1 | date = August 8, 2015 | doi = 10.16966/2470-1009.103 | url = https://sciforschenonline.org/journals/drug/article-data/JDRD-1-103/JDRD-1-103.pdf }}</ref> <ref name="Padalko,2004">{{Citation | last1 = Padalko | first1 = Elizaveta | author-link1 = | last2 = Nuyens | first2 = Dieter| author-link2 = | last3 = De Palma | first3 = Armando| author-link3 = | last4 = Verbeken | first4 = Erik | author-link4 = | last5 = Aerts | first5 = Joeri L. | author-link5 = | last6 = De Clercq | first6 = Erik | author-link6 = | last7 = Carmeliet | first7 = Pete | author-link7 = | last8 = Neyts1 | first8 = Johan | author-link8 = | title = The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis | journal =Antimicrobial Agents and Chemotherapy | volume = 48 | issue = 1 | pages = 267–274 | date = 2004 | pmid = 14693549 | doi = 10.1128/AAC.48.1.267-274.2004 }}</ref> <ref name="Suhadolnik,1994">{{Citation | last1 = Suhadolnik | first1 = RJ | author-link1 =Robert Suhadolnik | last2 = Reichenbach | first2 = NL | author-link2 = | last3 =Hitzges | first3 = P | author-link3 = | last4 = Sobol | first4 = RW | author-link4 = | last5 = Peterson | first5 = DL | author-link5 = Daniel Peterson | last6 = Henry | first6 = B | author-link6 = | last7 = Ablashi | first7 = DV | author-link8 = Dharam Ablashi | last8 = Müller | first8 = WE | author-link8 = | last9 =Schröder | first9 = HC | author-link9 = | last10= Carter | first10 = WA | author-link10 = William Carter | title = Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. | journal =Clinical Infectious Disease | volume = 18 | issue = Suppl 1 | page = S96-104 | date = January 1994 | pmid = 8148461 | url=| pages=|chapter=|edition=|isbn=}}</ref> <ref name="HemBio,2012">{{Cite web | last1 = Hemispherx Biopharma, Inc. | title = Ampligen® for the Treatment of Chronic Fatigue Syndrome | date = Dec 20, 2012 | url = http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM334430.pdf }}</ref> <ref name="Strayer,1994">{{Cite journal | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 = Carter | first2 = WA | author-link2 = William Carter | last3 = Brodsky | first3 = I | author-link3 = | last4 = Cheney | first4 = P | author-link4 = Paul Cheney | last5 = Peterson | first5 = D | author-link5 = Daniel Peterson | last6 = Salvato | first6 = P | author-link6 = | last7 = Thompson | first7 = C | author-link7 = | last8 = Loveless | first8 = M | author-link8 = | last9 = Shapiro | first9 = DE | author-link9 = | last10 = Elsasser | first10 = W | author-link10 = | title = A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome | journal = Clinical Infectious Diseases | volume = 18 | issue = Suppl 1 | pages = S88-95 | date = 1994 | pmid = 8148460 }}</ref> <ref name="Strayer,1995">{{Cite journal | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 = Carter | first2 = W | author-link2 = William Carter | last3 = Strauss | first3 = KI | author-link3 = Kenneth Strauss | last4 = Brodsky | first4 = I | author-link4 = | last5 = Suhadolnik | first5 = R | author-link5 = Robert Suhadolnik | last6 = Ablashi | first6 = D | author-link6 = Dharam Ablashi | last7 =Henry | first7 = B | author-link7 = | last8 = Mitchell | first8 = WM | author-link8 = William Mitchell | last9 = Bastien | first9 = S | author-link9 = | last10 = Peterson | first10 = D | author-link10 = Daniel Peterson | title = Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | pages = 35-53 | date = 1995 | url = http://www.tandfonline.com/doi/citedby/10.1300/J092v01n01_04?scroll=top&needAccess=true }}</ref> <ref name="Strayer, 2012">{{Citation | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 = Carter | first2 = WA | author-link2 = William Carter | last3 = Stouch | first3 = BC | author-link3 = | last4 = Stevens | first4 = SR | author-link4 = Staci Stevens | last5 = Bateman | first5 = L | author-link5 = Lucinda Bateman | last6 = Cimoch | first6 = PJ | author-link6 = | last7 = Lapp | first7 = CW | author-link8 = Charles Lapp | last8 = Peterson | first8 = DL | author-link8 = Daniel Peterson | last9 =Chronic Fatigue Syndrome AMP-516 Study Group | author-link9 = | last10= Mitchell | first10 = WM | author-link10 = William Mitchell | title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | journal = PLoS One | volume = 7 | issue = 3 | pages = e31334 | date = 2012 | pmid = 22431963 | doi = 10.1371/journal.pone.0031334 }}</ref> </references> [[Category:Potential treatments]] [[Category:Antivirals]] [[Category:Immunomodulators]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs